Last updated: September 4, 2026
Lamivudine is a mature, low-cost nucleoside reverse transcriptase inhibitor with broad generic supply and continuing use in HIV and hepatitis B treatment. Raltegravir potassium, marketed primarily as Isentress and Isentress HD by Merck, is an older integrase inhibitor facing therapeutic substitution from dolutegravir- and bictegravir-based regimens. The two active ingredients do not have a widely marketed FDA-approved fixed-dose combination product.
Lamivudine has limited remaining branded value as a standalone product but remains commercially relevant in combination products such as Dovato, Triumeq, Epivir, Combivir, and generic HIV regimens. Raltegravir has a more concentrated revenue exposure because Merck historically held the principal branded franchise, but its commercial trajectory has weakened as newer integrase inhibitors gained guideline preference and generic competition emerged.
What are lamivudine and raltegravir potassium used for?
Lamivudine is used with other antiretroviral agents to treat HIV-1 infection. It is also approved for chronic hepatitis B at a different dosage and under different product labeling. Lamivudine is present in several major HIV products:
| Product |
Active ingredients |
Principal commercial sponsor |
| Epivir |
Lamivudine |
ViiV Healthcare |
| Combivir |
Lamivudine, zidovudine |
ViiV Healthcare |
| Trizivir |
Lamivudine, zidovudine, abacavir |
ViiV Healthcare |
| Epzicom |
Lamivudine, abacavir |
ViiV Healthcare |
| Dovato |
Dolutegravir, lamivudine |
ViiV Healthcare |
| Triumeq |
Dolutegravir, abacavir, lamivudine |
ViiV Healthcare |
| Generic lamivudine |
Lamivudine |
Multiple manufacturers |
Raltegravir potassium is the active pharmaceutical ingredient in Isentress and Isentress HD. It inhibits HIV integrase, an enzyme required for viral DNA integration. The products are used with other antiretroviral drugs and are approved for adults and selected pediatric populations.[1]
| Product |
Strength or formulation |
Commercial sponsor |
| Isentress |
400 mg film-coated tablet |
Merck |
| Isentress HD |
600 mg tablet |
Merck |
| Isentress chewable tablets |
Pediatric formulation |
Merck |
| Raltegravir potassium generic |
Primarily 400 mg tablets |
Multiple manufacturers |
There is no major branded FDA-approved fixed-dose product combining lamivudine with raltegravir potassium. Clinicians may prescribe the two drugs together in selected regimens, but the combination is not a leading commercial product category.
What is the FDA regulatory status of lamivudine and raltegravir potassium?
Lamivudine received FDA approval in 1995 as Epivir. Its regulatory position is now mature. Multiple abbreviated new drug applications cover lamivudine tablets and oral solution, while lamivudine is also included in approved fixed-dose combination products.[2]
Raltegravir received FDA approval in 2007 as Isentress. Isentress HD was approved in 2017 as a once-daily formulation for adults and pediatric patients meeting specified weight criteria.[3]
The regulatory profile is summarized below:
| Attribute |
Lamivudine |
Raltegravir potassium |
| Initial U.S. approval |
1995 |
2007 |
| Drug class |
NRTI |
Integrase strand transfer inhibitor |
| Primary brand |
Epivir |
Isentress |
| Major generic pathway |
ANDA |
ANDA |
| Biologic status |
Small molecule |
Small molecule |
| Biosimilar exposure |
None |
None |
| Current regulatory risk |
Low |
Low to moderate, concentrated in formulation and product-specific approvals |
| Main competitive pressure |
Other NRTIs and combination products |
Dolutegravir, bictegravir, elvitegravir, cabotegravir |
Because both products are small-molecule drugs, biosimilar regulation does not apply. The relevant competitive pathway is generic ANDA approval, not the 351(k) biosimilar pathway.
What patents protect lamivudine?
The core lamivudine patent estate is expired in the United States and other major markets. The compound was discovered and commercialized decades ago, and generic versions entered the market after loss of primary patent protection.
A historically important U.S. patent was U.S. Patent No. 5,047,407, which covered lamivudine-related nucleoside compounds. Its effective exclusivity period ended long before the current market cycle. Orange Book protection for standalone lamivudine is therefore no longer a material barrier to generic entry.[4]
Current protection around lamivudine generally arises from:
- Combination-product patents.
- Formulation claims.
- Specific therapeutic uses.
- Patents covering partner molecules, especially dolutegravir in Dovato and abacavir or dolutegravir in other combinations.
- Regulatory exclusivity or pediatric extensions attached to newer combination products.
The commercial distinction is important. Lamivudine itself is largely unprotected, but a product containing lamivudine may still have enforceable patents directed to the other active ingredient, the fixed-dose combination, or a specific method of use.
What formulations are protected by lamivudine patents?
Standalone lamivudine tablets and oral solutions are not protected by a strong current U.S. composition-of-matter estate. Patent risk is more relevant for combination products.
Dovato, which combines dolutegravir and lamivudine, has historically obtained commercial protection from patents directed primarily to the dolutegravir component, combination use, and product-specific claims. Triumeq has a similar structure, with protection tied to the combination and its active ingredients rather than to lamivudine alone.
A generic manufacturer seeking to copy a lamivudine combination must therefore analyze the full product patent landscape, not only lamivudine patents.
What patents protect raltegravir potassium?
The core U.S. raltegravir patent was U.S. Patent No. 7,169,780, assigned to Merck and covering hydroxypyrimidinone carboxamide integrase inhibitors, including raltegravir. The patent had an original expiration date in 2022, with pediatric exclusivity extending protection into 2023.[5]
The core compound protection has expired. Later patents and regulatory rights were directed to matters such as:
- Raltegravir formulations.
- Tablet composition.
- Dosing schedules.
- Pediatric presentations.
- The Isentress HD 600 mg formulation.
- Manufacturing and solid-state properties.
The practical effect is a split patent position. The central molecule is open to generic competition, while particular strengths, dosage forms, and labeling claims may have had later-dated protection.
| Patent category |
Commercial effect |
| Core raltegravir compound patent |
Expired |
| Pediatric exclusivity |
Ended in 2023 for the original product cycle |
| 400 mg tablet patents |
Reduced barrier after core expiry; product-specific claims required review |
| 600 mg Isentress HD patents |
Potentially later protection than the original 400 mg product |
| Chewable and pediatric formulations |
Narrower market and potentially separate formulation claims |
| Manufacturing patents |
Possible process barriers, but limited ability to block all generic entry |
When did lamivudine and raltegravir lose exclusivity?
Lamivudine lost meaningful standalone exclusivity more than a decade ago. Raltegravir reached the end of its principal compound protection in 2022, with pediatric exclusivity extending the relevant period into 2023.
| Drug |
Initial approval |
Principal exclusivity event |
Current position |
| Lamivudine |
1995 |
Core patents expired years ago |
Generic, multi-source market |
| Raltegravir potassium |
2007 |
Core patent expired in 2022; pediatric extension into 2023 |
Generic entry and rapid branded erosion |
| Isentress HD |
2017 |
Product-specific rights may extend beyond core compound protection |
Narrower branded defense |
| Dovato |
2019 |
Combination and component patents remain commercially relevant |
Branded combination product with later-life-cycle protection |
The absence of core compound protection does not eliminate all patent litigation. A generic applicant may still face claims involving formulation, dosage, method of treatment, or a related combination product.
Which companies are challenging lamivudine and raltegravir patents?
Generic competition for lamivudine includes large and regional manufacturers such as Teva, Viatris, Cipla, Aurobindo, Hetero, Sun Pharma, and Dr. Reddy's, depending on jurisdiction and product presentation. The market includes both finished-dose manufacturers and vertically integrated suppliers.
Raltegravir generic competition has also involved major ANDA manufacturers, including companies active in HIV generics such as Lupin, Aurobindo, Teva, Mylan or Viatris, and other regional suppliers. The most important commercial event was the transition from a Merck-controlled branded market to an ANDA market following expiration of core protection.
Paragraph IV risk was most material before the 2022 to 2023 expiration window. Once the principal compound patent expired, the economic value of further Paragraph IV litigation declined. Remaining disputes would be narrower and more likely to target a specific dosage form, formulation, or method-of-use claim.
What is the Orange Book status of lamivudine and Isentress?
Lamivudine's standalone Orange Book position is primarily historical. Current market access depends on approved generic applications rather than an active composition-of-matter patent blocking the molecule.
Isentress historically had Orange Book-listed patents covering raltegravir and related product protections. The principal compound patent has expired. Any remaining listing must be evaluated by product strength and formulation, especially when comparing Isentress 400 mg, Isentress HD 600 mg, chewable tablets, and oral suspension presentations.[6]
A generic company can enter without infringing an unexpired patent by:
- Filing a Paragraph III certification with delayed launch.
- Filing a Paragraph IV certification challenging an unexpired patent.
- Using a section viii statement to omit a patented method of use.
- Launching after patent expiration or settlement.
- Designing around a formulation or dosage claim.
The precise launch date depends on the ANDA approval status, patent listings applicable to the targeted product, litigation outcomes, and any settlement restrictions.
How strong is the patent estate for each drug?
Lamivudine has a weak standalone patent estate and a stronger combination-product position. Raltegravir has a weak post-expiration compound estate but a more meaningful historical record of formulation and product-specific protection.
| Factor |
Lamivudine |
Raltegravir potassium |
| Core composition patent |
Expired |
Expired |
| Current standalone barrier |
Very low |
Low |
| Combination-product protection |
Moderate for newer products |
Limited relative to core patent |
| Formulation complexity |
Low |
Moderate |
| Generic manufacturing access |
Broad |
Broad but less commoditized |
| Litigation value |
Concentrated in combinations |
Concentrated in formulations and dosage forms |
| Life-cycle management |
Dovato, Triumeq, hepatitis B products |
Isentress HD and pediatric forms |
For investors, the key distinction is that lamivudine continues to earn value through inclusion in newer combinations, while raltegravir's value is tied more directly to a declining legacy brand.
What is the financial trajectory for lamivudine?
Lamivudine's financial profile is fragmented. ViiV Healthcare does not rely primarily on standalone Epivir revenue. The ingredient contributes to several combination products, including Dovato and Triumeq, whose commercial value depends on the full regimen and the non-lamivudine components.
The market has three tiers:
- Low-margin generic lamivudine.
- Branded legacy products such as Epivir.
- Higher-value combination products where lamivudine is one component of a protected regimen.
Generic lamivudine is exposed to price compression because the API and finished-dose technology are mature, multiple suppliers exist, and HIV treatment programs often use centralized procurement. Volume remains durable because of global HIV prevalence, public-health treatment programs, and lamivudine's role in simplified regimens.
Lamivudine's strongest financial defense is not molecule-level exclusivity. It is continued inclusion in guideline-supported combinations. Dovato has been particularly important because it uses a two-drug regimen based on dolutegravir and lamivudine. The product competes against Biktarvy and other complete regimens rather than against standalone lamivudine.
What is the financial trajectory for raltegravir potassium?
Raltegravir's branded revenue has declined from its earlier peak. Isentress was one of the first widely adopted integrase inhibitors, but the class shifted toward once-daily, high-barrier regimens led by dolutegravir and bictegravir.
Key causes of erosion include:
- Generic entry after core patent expiry.
- Prescriber migration to newer integrase inhibitors.
- Greater use of single-tablet regimens.
- Competition from Dovato, Triumeq, Biktarvy, Tivicay-based regimens, and long-acting cabotegravir.
- Lower commercial importance of twice-daily Isentress in treatment-naive adults.
- Price pressure in public and institutional procurement.
Merck reports Isentress and Isentress HD sales as part of its pharmaceutical product portfolio. The franchise has moved from a high-value growth product to a mature, declining asset, with residual revenue supported by treatment-experienced patients, pediatric use, tolerability considerations, and markets where cost or formulary position favors raltegravir.[7]
Raltegravir's remaining value is stronger in selected clinical niches than in broad first-line treatment. Its commercial ceiling is constrained by the availability of newer integrase inhibitors with simpler dosing and stronger market access.
How does lamivudine compare with raltegravir potassium?
| Commercial metric |
Lamivudine |
Raltegravir potassium |
| Market maturity |
Very mature |
Mature, with branded decline |
| Generic intensity |
Very high |
Increasing to high |
| Current branded value |
Primarily in combinations |
Isentress legacy franchise |
| Main clinical role |
Backbone NRTI and combination component |
Integrase inhibitor |
| Preferred modern substitutes |
Tenofovir-based and newer combination regimens |
Dolutegravir and bictegravir |
| Patent strength |
Weak standalone, stronger in combinations |
Core patent expired; residual formulation rights |
| Revenue outlook |
Stable volume, low unit price |
Declining branded revenue and generic price erosion |
| Manufacturing barrier |
Low |
Moderate |
| Geographic opportunity |
Broad, especially emerging markets |
Selective, dependent on local guidelines and price |
Lamivudine has the more durable volume profile. Raltegravir has the more visible historical brand revenue but faces greater substitution risk.
What generic launch scenarios exist?
The most likely market scenarios are:
Lamivudine
Generic lamivudine remains widely available. New entrants can compete through lower pricing, regional tenders, dual sourcing, and combination products. The principal challenge is not patent access but margin compression and regulatory compliance.
Raltegravir potassium
Generic raltegravir can enter through approved 400 mg products and, subject to applicable rights, other presentations. The commercial launch opportunity is strongest where:
- Merck pricing remains above generic cost.
- Public tenders seek integrase inhibitor alternatives.
- Treatment-experienced patients continue to use raltegravir.
- Pediatric demand supports chewable or liquid presentations.
- Local regulatory approval is faster than competitor approval.
A successful generic launch is unlikely to recreate the historical Isentress revenue base because the underlying market has shifted toward newer integrase inhibitors.
What manufacturing and geographic barriers affect the market?
Lamivudine manufacturing is widely distributed across India, China, Europe, and other pharmaceutical production centers. Its synthesis is established, and finished-dose competition is extensive. The main barriers are quality systems, regulatory approval, supply reliability, and tender access.
Raltegravir potassium has a more specialized synthesis and formulation profile, but the manufacturing barrier is not strong enough to preserve meaningful molecule-level exclusivity. Suppliers must manage API quality, polymorphism or solid-state characteristics, formulation performance, and bioequivalence requirements.
Geographic dynamics differ:
- United States: mature generic market, strong price competition, and declining Isentress brand value.
- Europe: national reimbursement and tender systems drive product selection.
- Low- and middle-income countries: lamivudine has broad public-health demand; raltegravir demand is more dependent on HIV treatment guidelines and procurement pricing.
- Asia-Pacific: large generic manufacturing base and expanding treatment volumes create supply-side competition.
- Latin America: government procurement and local registration requirements influence entry timing.
What litigation and settlement issues affect the products?
Lamivudine litigation is now concentrated in combination products and newer branded regimens. Standalone lamivudine litigation has limited commercial significance because core protection expired long ago.
Raltegravir litigation was more relevant before expiration of Merck's core patent. Generic applicants could challenge listed patents under Paragraph IV, while Merck could seek a 30-month stay under the Hatch-Waxman framework after receiving notice of a qualifying certification. After core patent expiry and pediatric exclusivity expiration, remaining disputes became narrower.
Settlement agreements, where used, may have controlled launch dates, authorized generic terms, or product-specific restrictions. A settlement for one raltegravir strength does not automatically resolve patent exposure for all presentations.
Key Takeaways
- Lamivudine is a mature, low-cost generic molecule with continuing strategic value in Dovato, Triumeq, and other combination products.
- Raltegravir potassium lost core U.S. patent protection in 2022, with pediatric exclusivity extending the relevant period into 2023.
- The principal commercial risk to Isentress is therapeutic substitution by dolutegravir, bictegravir, and long-acting cabotegravir.
- Lamivudine has stronger long-term volume durability, while raltegravir has greater branded revenue erosion.
- Neither active ingredient has biosimilar risk because both are small molecules.
- Remaining patent value is concentrated in formulations, dosage forms, methods of use, and combination products.
- Generic access is primarily constrained by regulatory approval, manufacturing quality, pricing, and market access rather than core molecule patents.
FAQs
Is lamivudine still commercially important after patent expiration?
Yes. Lamivudine has low standalone pricing but remains important because it is embedded in branded and generic HIV combinations, including Dovato and Triumeq.
Can a generic company launch lamivudine without challenging patents?
Yes. Standalone lamivudine core patents have expired. A company copying a combination product must separately evaluate patents covering the partner drug, formulation, dosage, or method of use.
Is raltegravir potassium still protected by Merck patents?
The principal compound patent has expired. Product-specific formulation, dosage, pediatric, or manufacturing patents may have had later expiration dates and require separate product-level analysis.
Is there a fixed-dose lamivudine and raltegravir tablet?
There is no major FDA-approved fixed-dose combination product containing only lamivudine and raltegravir potassium. The drugs can be used together clinically, but they are generally supplied as separate products.
Which drug has the stronger future market outlook?
Lamivudine has the stronger volume outlook because it remains a flexible component of multiple regimens and public-health programs. Raltegravir has a weaker outlook because newer integrase inhibitors offer simpler dosing and have displaced it in much of the first-line market.
References
-
Merck & Co., Inc. (2024). Isentress and Isentress HD prescribing information. U.S. Food and Drug Administration labeling database.
-
U.S. Food and Drug Administration. (2024). Epivir, lamivudine, and related approved drug products. Drugs@FDA.
-
U.S. Food and Drug Administration. (2017). FDA approves new formulation of Isentress for HIV treatment. FDA drug approval materials.
-
U.S. Patent and Trademark Office. (1991). U.S. Patent No. 5,047,407: 2',3'-dideoxy-beta-L-pentofuranosyl nucleosides. Washington, DC.
-
U.S. Patent and Trademark Office. (2007). U.S. Patent No. 7,169,780: Hydroxypyrimidinone carboxamide compounds. Washington, DC.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
Merck & Co., Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Whitehouse Station, NJ.
